Australia markets closed

Centogene N.V. (CNTG)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
2.6500+0.1800 (+7.29%)
At close: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close2.4700
Open2.3900
Bid2.6500 x 2200
Ask2.7700 x 900
Day's range2.3700 - 2.8295
52-week range1.8300 - 11.9500
Volume5,847
Avg. volume9,127
Market cap71.739M
Beta (5Y monthly)-1.19
PE ratio (TTM)N/A
EPS (TTM)-2.1970
Earnings date01 July 2022 - 03 July 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est9.89
  • GlobeNewswire

    CENTOGENE Announces Shareholder Approval of All Resolutions at 2022 Annual General Meeting

    CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 27, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the commercial-stage, essential biodata life science partner for rare and neurodegenerative diseases, today announced the voting results of the Company’s Annual General Meeting. Shareholders voted in favor of all proposals, which included the appointment of Miguel Coego Rios as Managing Director and Chief Financial Officer. The shareholders adopted the Dutch statutory annual account

  • GlobeNewswire

    CENTOGENE Announces Appointment of Miguel Coego Rios as Chief Financial Officer

    Interim CFO Miguel Coego Rios appointed as Managing Director and permanent CFOCAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, June 27, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the commercial-stage, essential biodata life science partner for rare and neurodegenerative diseases, today announced the appointment of Miguel Coego Rios as Managing Director and Chief Financial Officer of the Company, effective June 22, 2022. “As we continue to make progress on pivoting the organization

  • GlobeNewswire

    CENTOGENE and Agios Expand Partnership for Clinical Development of PYRUKYND® (mitapivat) to Treat Children With Rare Blood Disease

    Working together on the world’s first treatment that targets the underlying causes of pyruvate kinase (“PK”) deficiency in children under the age of 18Expanded collaboration to include Phase 3 ACTIVATE-kids and ACTIVATE-kidsT studies CENTOGENE’s genetic testing and Biodatabank identify causative mutations, including the UGT1A1 and PKLR genes, and supports precise diagnosis CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 13, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the comme